Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$24.40 -3.7%	$22.70	$16.50 ▼ $26.55	$2.21B	N/A	59,959 shs	16,331 shs
DNTH Dianthus Therapeutics	$17.42 -2.4%	$18.95	$13.37 ▼ $32.27	$560.23M	1.48	276,070 shs	238,844 shs
HCM HUTCHMED	$13.77 -0.6%	$14.08	$11.51 ▼ $21.50	$2.40B	0.55	100,986 shs	87,577 shs
XENE Xenon Pharmaceuticals	$28.72 -1.1%	$33.00	$26.74 ▼ $46.00	$2.20B	1.21	542,510 shs	2.46 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	0.00%	-7.85%	-2.98%	+28.22%	+2,439,999,900.00%
DNTH Dianthus Therapeutics	0.00%	-5.43%	-19.72%	-19.35%	-21.39%
HCM HUTCHMED	0.00%	+2.76%	-6.96%	-16.34%	-26.21%
XENE Xenon Pharmaceuticals	0.00%	-3.46%	-24.60%	-22.42%	-24.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	1.5116 of 5 stars	3.6	0.0	0.0	0.0	3.4	0.8	0.0
HCM HUTCHMED	2.193 of 5 stars	3.0	2.0	0.0	0.0	2.9	0.0	1.9
XENE Xenon Pharmaceuticals	3.5351 of 5 stars	4.5	4.0	0.0	0.0	3.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
DNTH Dianthus Therapeutics	3.22	Buy	$53.00	204.25% Upside
HCM HUTCHMED	2.00	Hold	$19.00	37.98% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$54.82	90.87% Upside

Current Analyst Ratings Breakdown

Latest DNTH, HCM, AAPG, and XENE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	XENE Xenon Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
5/13/2025	DNTH Dianthus Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $50.00
5/13/2025	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
5/13/2025	HCM HUTCHMED	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/13/2025	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $47.00
5/13/2025	XENE Xenon Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00
5/13/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $55.00
5/7/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$55.00
5/5/2025	XENE Xenon Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$980.65M	2.17	N/A	N/A	N/A	∞
DNTH Dianthus Therapeutics	$6.52M	85.87	N/A	N/A	$11.40 per share	1.53
HCM HUTCHMED	$630.20M	3.81	$0.56 per share	24.51	$4.27 per share	3.22
XENE Xenon Pharmaceuticals	$7.50M	293.84	N/A	N/A	$14.18 per share	2.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	-$43.56M	-$2.88	N/A	N/A	N/A	-1,250.32%	-21.68%	-20.88%	8/7/2025 (Estimated)
HCM HUTCHMED	$100.78M	N/A	0.00	9.43	N/A	N/A	N/A	N/A	6/18/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$182.39M	-$3.23	N/A	N/A	N/A	N/A	-24.69%	-23.68%	8/14/2025 (Estimated)

Latest DNTH, HCM, AAPG, and XENE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.82	+$0.04	-$0.82	$0.81 million	$1.16 million
5/12/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.90	-$0.83	+$0.07	-$0.83	$1.64 million	$7.50 million
3/11/2025	Q4 2024	DNTH Dianthus Therapeutics	-$0.85	-$0.81	+$0.04	-$0.81	$1.40 million	$1.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	18.30	18.30
HCM HUTCHMED	0.07	2.81	2.68
XENE Xenon Pharmaceuticals	N/A	22.21	22.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
DNTH Dianthus Therapeutics	47.53%
HCM HUTCHMED	8.82%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
DNTH Dianthus Therapeutics	8.15%
HCM HUTCHMED	3.60%
XENE Xenon Pharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.11 million	N/A	N/A
DNTH Dianthus Therapeutics	80	32.16 million	24.70 million	Optionable
HCM HUTCHMED	1,760	174.32 million	168.04 million	Not Optionable
XENE Xenon Pharmaceuticals	210	76.73 million	72.03 million	Optionable

DNTH, HCM, AAPG, and XENE Headlines

Recent News About These Companies

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Bank of America Corp DE

May 31 at 3:14 AM | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 30 at 4:01 PM | globenewswire.com

Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)

May 30 at 2:31 AM | marketbeat.com

Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 28, 2025 | marketbeat.com

Woodline Partners LP Makes New $1.57 Million Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27, 2025 | marketbeat.com

Two Sigma Investments LP Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Position Lifted by Millennium Management LLC

May 26, 2025 | marketbeat.com

Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 26, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Two Sigma Advisers LP

May 25, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com

May 23, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by Brokerages

May 23, 2025 | marketbeat.com

Fair Value analysis proves accurate as XENE drops 37% from February 2024 peak

May 21, 2025 | investing.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Vestal Point Capital LP

May 21, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Sells 117,919 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 21, 2025 | marketbeat.com

Ensign Peak Advisors Inc Sells 136,970 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 19, 2025 | marketbeat.com

Leerink Partnrs Issues Optimistic Forecast for XENE Earnings

May 18, 2025 | marketbeat.com

Sphera Funds Management LTD. Acquires Shares of 52,097 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 18, 2025 | marketbeat.com

Polar Capital Holdings Plc Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 17, 2025 | marketbeat.com

HC Wainwright Issues Positive Outlook for XENE Earnings

May 17, 2025 | marketbeat.com

Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

May 17, 2025 | marketbeat.com

MPM Bioimpact LLC Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH, HCM, AAPG, and XENE Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$24.40 -0.95 (-3.75%)

As of 05/30/2025 02:44 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Dianthus Therapeutics NASDAQ:DNTH

$17.42 -0.43 (-2.41%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$17.35 -0.07 (-0.40%)

As of 05/30/2025 04:04 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

HUTCHMED NASDAQ:HCM

$13.77 -0.09 (-0.65%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$13.83 +0.06 (+0.44%)

As of 05/30/2025 06:13 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Xenon Pharmaceuticals NASDAQ:XENE

$28.72 -0.32 (-1.10%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$28.84 +0.12 (+0.42%)

As of 05/30/2025 04:33 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time